What's in Alvotech Swiss AG's pipeline?

Alvotech Swiss AG has 14 drugs in our index: 1 marketed, 0 filed, 7 in Phase 3, 0 in Phase 2, 6 in Phase 1.

Which companies overlap with Alvotech Swiss AG's portfolio?

Top competitors by shared drug class: Celltrion, Abbott, Innovaderm Research Inc., Samsung Bioepis Co., Ltd., Amgen.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/alvotech-swiss-ag.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Alvotech Swiss AG — Portfolio Competitive Intelligence Brief

Alvotech Swiss AG pipeline: 1 marketed, 0 filed, 7 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 7 Phase 3 0 Phase 2 6 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Simponi	Simponi	marketed		Tumor necrosis factor	Oncology
AVT03	AVT03	phase 3	TNF-α inhibitor (monoclonal antibody biosimilar)	TNF-α (tumor necrosis factor-alpha)	Immunology / Rheumatology
Eylea HD (aflibercept HD)	Eylea HD (aflibercept HD)	phase 3	VEGF inhibitor / Antiangiogenic agent	VEGF-A, PlGF (Placental Growth Factor)	Ophthalmology
Adalimumab biosimilar	Adalimumab biosimilar	phase 3	TNF-alpha inhibitor	TNF-alpha (Tumor Necrosis Factor-alpha)	Immunology
Simponi (Golimumab)	Simponi (Golimumab)	phase 3	TNF-alpha inhibitor	TNF-alpha	Immunology
Adalimumab originator	Adalimumab originator	phase 3	TNF-α inhibitor	TNF-α (Tumor Necrosis Factor-alpha)	Immunology
Eylea® (Aflibercept)	Eylea® (Aflibercept)	phase 3	VEGF inhibitor / Soluble decoy receptor	VEGF-A, VEGF-B, PlGF (Placental Growth Factor)	Ophthalmology
AVT04	AVT04	phase 3	VEGF inhibitor (monoclonal antibody); biosimilar	VEGF (Vascular Endothelial Growth Factor)	Oncology

Therapeutic area mix

Immunology · 3
Oncology · 2
Ophthalmology · 2
Immunology / Rheumatology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Celltrion · 2 shared drug classes
Abbott · 2 shared drug classes
Innovaderm Research Inc. · 2 shared drug classes
Samsung Bioepis Co., Ltd. · 2 shared drug classes
Amgen · 1 shared drug class
Asan Medical Center · 1 shared drug class
Altuğ Güner · 1 shared drug class
Assistance Publique Hopitaux De Marseille · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Alvotech Swiss AG:

Cite this brief

Drug Landscape (2026). Alvotech Swiss AG — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/alvotech-swiss-ag. Accessed 2026-05-16.